Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-19
    E.g., 2018-11-19

Articles

Pages

35498 items
11:13 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Sobi springboards U.S. growth in deal for AZ's Synagis

Swedish Orphan Biovitrum AB (SSE:SOBI) obtained U.S. rights to commercialize infectious disease drug Synagis palivizumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $1.5 billion up front. Sobi called the deal, which also includes profit sharing with...
10:01 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Oxford BioDynamics partners EpiSwitch platform

Oxford BioDynamics plc (LSE:OBD) said it partnered with an undisclosed major U.S. pharma to use its EpiSwitch epigenetic biomarker platform to develop predictive biomarkers for immuno-oncology therapeutics. The company did not respond to inquiries. Oxford BioDynamics...
10:00 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

SVB acquiring Leerink amid record year for IPOs

With IPOs continuing at a torrid pace, SVB Financial Group (NASDAQ:SIVB), the parent company of high-tech commercial lender Silicon Valley Bank, announced on Oct. 13 that it will acquire Leerink Partners for $280 million. Leerink, a...
9:55 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Daiichi, GSK to dissolve vaccines JV

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) agreed to dissolve their JV, Japan Vaccine Co. Ltd. In a statement, Daiichi said, “in consideration of changes in the Japan Vaccine business situation, both...
9:44 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

AbbVie strengthens early stage neurology focus with Mission deal

Mission Therapeutics Ltd. (Cambridge, U.K.) and AbbVie Inc. (NYSE:ABBV) partnered to develop deubiquitinase inhibitors for Alzheimer's and Parkinson's diseases. The deal is the second in as many weeks for AbbVie for early stage neurology candidates. Deubiquitinases,...
9:40 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Helperby, UCLA to explore antibiotic combos

Helperby Therapeutics Ltd. (London, U.K.) partnered with University of California Los Angeles (Los Angeles, Calif.) to develop undisclosed combinations of antibiotics. The partners will target antimicrobial resistant bacteria and under the deal will share data and...
9:33 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

MaxCyte partners with Kite, CRISPR in nonviral gene editing deals

MaxCyte Inc. (LSE:MXCT) partnered with Kite Pharma Inc. and expanded an existing deal with CRISPR Therapeutics AG (NASDAQ:CRSP) to use its Flow Electroporation technology to engineer cells. Kite gains a non-exclusive license to use MaxCyte's...
9:29 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Oxurion, Beta Therapeutics partner to develop heparanase inhibitors

Oxurion N.V. (Euronext:OXUR) and Beta Therapeutics Pty. Ltd. (Canberra, Australia) partnered to develop heparanase inhibitors to treat retinal disorders, including dry age-related macular degeneration (AMD). Oxurion will have an exclusive option to license the heparanase inhibitor...
8:01 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

MEI Pharma outlicenses PI3K inhibitor to Kyowa in Japan, BeiGene in China

MEI Pharma Inc. (NASDAQ:MEIP) granted Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) exclusive rights in Japan to develop and commercialize ME-401, initially for relapsed or refractory follicular lymphoma. ME-401 is a phosphoinositide 3-kinase δ (PI3Kδ) inhibitor....
8:01 AM, Nov 16, 2018  |  BC Week In Review | Company News  |  Deals

Theravance sells Vibativ to Cumberland

Theravance Biopharma Inc. (NASDAQ:TBPH) sold antibiotic Vibativ telavancin to Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) for $25 million. Theravance is eligible for tiered royalties of up to 20%. Theravance recorded $5.4 million in Vibativ sales in 2Q18....

Pages